Morepen Laboratories Limited — Others, 12-05-2025: Appointment

Morepen Laboratories Limited has announced a board meeting approving the financial results for the quarter and financial year ended March 31, 2025, with clean auditor reports. The Board approved a final dividend of Rs. 0.20 per share, subject to shareholder approval. The company revised the appointed date for transferring its medical devices business to subsidiary Morepen Medipath Limited, which plans to set up a wholly owned step-down subsidiary in Dubai to grow its medical device operations. Consolidated revenue was Rs. 470.46 Cr with net profit of Rs. 118.02 Cr. Earnings per share stood at Rs. 2.20 consolidated and Rs. 1.90 standalone. Effective holding in Dr. Morepen Limited dropped to 80% after a share allotment, making Quick Med Private Limited a step-down subsidiary through an 80% acquisition by Dr. Morepen.